These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 2650258)

  • 1. Modulation of lymphocytotoxic activity in highly sensitised patients by anti-idiotypic antibodies.
    MacLeod AM; al-Muzairai IA; Innes A; Power DA; Stewart KN; Catto GR
    Transplant Proc; 1989 Feb; 21(1 Pt 1):756-7. PubMed ID: 2650258
    [No Abstract]   [Full Text] [Related]  

  • 2. Anti-idiotypic activity in cytotoxic sera from highly sensitised patients (HSP) given cyclosporin A and blood transfusion from a specific donor (ST).
    al-Muzairai IA; MacLeod AM; Cochrane S; Jones MC; Propper D; Catto GR
    Transplant Proc; 1989 Feb; 21(1 Pt 1):748-9. PubMed ID: 2650254
    [No Abstract]   [Full Text] [Related]  

  • 3. Development of class I-directed lymphocytotoxic antibodies after liver transplantation.
    Bryan CF; Newman JT; Tillquist RL; Husberg B; Klintmalm GB; Stone MJ
    Transplant Proc; 1987 Feb; 19(1 Pt 3):2392-3. PubMed ID: 3274523
    [No Abstract]   [Full Text] [Related]  

  • 4. Antiidiotypic activity in sera from sensitised potential transplant recipients.
    al Muzairai IA; MacLeod AM; Innes A; Cunningham C; Stewart KN; Power DA; Catto GR
    Nephrol Dial Transplant; 1988; 3(6):803-8. PubMed ID: 3147424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-idiotypic antibodies to HLA after donor-specific blood transfusion (DST).
    Pohanka E; Manfro RC; Oto C; Colombe BW; Melzer J; Feduska N; Salvatierra O; Garovoy MR
    Transplant Proc; 1989 Feb; 21(1 Pt 2):1806-9. PubMed ID: 2652590
    [No Abstract]   [Full Text] [Related]  

  • 6. Anti-idiotypes against autoantibodies and alloantibodies to VIII:C (anti-haemophilic factor) are present in therapeutic polyspecific normal immunoglobulins.
    Rossi F; Sultan Y; Kazatchkine MD
    Clin Exp Immunol; 1988 Nov; 74(2):311-6. PubMed ID: 3147154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of anti-Fab and anti-IgG antibodies with high kidney transplant survival.
    Chia D; Horimi T; Terasaki PI; Hermes M
    Transplant Proc; 1982 Jun; 14(2):322-4. PubMed ID: 7051474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of anti-idiotypic antibodies to HLA (anti-anti-HLA antibodies) by use of human monoclonal antibodies.
    Pistillo MP; Ferrara GB; Reed E; Brensilver J; McCabe R; Benvensity A; Hardy M; King DW; Suciu-Foca N
    Transplant Proc; 1989 Feb; 21(1 Pt 1):760-1. PubMed ID: 2650260
    [No Abstract]   [Full Text] [Related]  

  • 9. Characterization of protective anti-Fab autoantibodies in kidney graft recipients.
    Süsal C; Groth J; Tanzi-Fetta RF; Kirste G; Doerr C; Terness P; May G; Staehler G; Opelz G
    Transplant Proc; 1992 Dec; 24(6):2523-6. PubMed ID: 1465853
    [No Abstract]   [Full Text] [Related]  

  • 10. Anti-idiotypic antibodies against anti-phospholipid autoantibodies which suppress lupus-like anticoagulant activity.
    Gris JC; Schved JF; Tousch D; Hereil S; Feugeas O
    Nouv Rev Fr Hematol (1978); 1988; 30(3):143-7. PubMed ID: 3138656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of anti-F(ab)2 gamma antibodies by buffy coat transfusions and their effect in kidney transplantation.
    Süsal C; Guo Z; Terness P; Padányi A; Petrányi G; Opelz G
    Transplant Proc; 1990 Aug; 22(4):1893-4. PubMed ID: 2389476
    [No Abstract]   [Full Text] [Related]  

  • 12. Anti-idiotypic antibodies regulate the immune response to HLA in heart allograft recipients.
    Reed E; Rouah C; Hsu D; Cechova K; Rose E; Smith C; Reemstma K; King DW; Suciu-Foca N
    Transplant Proc; 1989 Feb; 21(1 Pt 1):463-4. PubMed ID: 2650178
    [No Abstract]   [Full Text] [Related]  

  • 13. The lymphocytotoxic reaction: the mechanism of rabbit complement action.
    Ferrone S; Cooper NR; Pellegrino MA; Reisfeld RA
    J Immunol; 1971 Oct; 107(4):939-47. PubMed ID: 4999260
    [No Abstract]   [Full Text] [Related]  

  • 14. Absence of irreversible rejection in the presence of warm anti-donor-HLA class I cytotoxic IgG antibody.
    Shoker A; Klassen J; Herbut B
    Clin Nephrol; 1997 Feb; 47(2):87-91. PubMed ID: 9049455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiidiotypic activity and sensitization after donor-specific transfusion (DST) given with and without cyclosporin A (CsA).
    Hillis AN; MacLeod AM; al-Muzairai IA; Innes A; Stewart KN; Power DA; Bone MJ; Sells RA; Catto GR
    Transplant Proc; 1989 Feb; 21(1 Pt 2):1820-1. PubMed ID: 2652591
    [No Abstract]   [Full Text] [Related]  

  • 16. Immunologic monitoring of transplant patients.
    Carpenter CB; Morris PJ
    Transplant Proc; 1979 Mar; 11(1):1153-7. PubMed ID: 377614
    [No Abstract]   [Full Text] [Related]  

  • 17. The use of Fab fragments of anti-human immunoglobulin as analytic tools for establishing the involvement of immunoglobulin in the spontaneous cytotoxicity to cultured tumor cells by lymphocytes from patients with bladder carcinoma and from healthy donors.
    Troye M; Perlmann P; Pape GR; Spiegelberg HL; Näslund I; Gidlöf A
    J Immunol; 1977 Sep; 119(3):1061-7. PubMed ID: 302271
    [No Abstract]   [Full Text] [Related]  

  • 18. Idiotypic network: possible explanation of seronegativity in a patient with rheumatoid arthritis.
    Pasquali JL; Urlacher A; Storck D
    Clin Exp Immunol; 1984 Feb; 55(2):281-6. PubMed ID: 6697565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transplant-induced donor-specific antibodies and graft outcome.
    Martin S; Dyer PA; Mallick NP; Gokal R; Johnson RW
    Transplant Proc; 1987 Feb; 19(1 Pt 1):899-90. PubMed ID: 3274886
    [No Abstract]   [Full Text] [Related]  

  • 20. Idiotypic determinants on human T cells and modulation of human T cell responses by anti-idiotypic antibodies.
    Geha RS
    J Immunol; 1984 Oct; 133(4):1846-51. PubMed ID: 6206140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.